Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: A randomized clinical trial

Diseases of the Esophagus

Volumn 25, Issue 5, 2012, Pages 373-380

  Manabe, N ^a   Haruma, K ^a   Ito, M ^b   Takahashi, N ^e   Takasugi, H ^f   Wada, Y ^b   Nakata, H ^g   Katoh, T ^h   Miyamoto, M ^c   Tanaka, S ^d  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^d HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^e Takahashi Family Clinic   (Japan)

^f Ohguro Gastroenterology Hospital   (Japan)

^g Nakata Gastroenterological and Internal Medical Clinic   (Japan)

^h Kusaka Internal Medical Clinic   (Japan)

Author keywords

Nonerosive reflux disease; Proton pump inhibitor; Sodium alginate

Indexed keywords

ALGINIC ACID; ALLOID G; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; EPIGASTRIC PAIN; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON EROSIVE REFLUX DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AGED; ALGINATES; DEGLUTITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; GLUCURONIC ACID; HEARTBURN; HEXURONIC ACIDS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84863482191     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2011.01276.x     Document Type: Article

References (40)

1. Vakil N, van Zanten S V, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
2. Manabe N, Haruma K, Mihara M etal. The increasing incidence of reflux esophagitis during the past 20 years in Japan. Gastroenterology 1999; 166: A244 [abstract].
3. Mishima I, Adachi K, Arima N etal. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol 2005; 40: 1005-9.
4. Armstrong D, Bennett J R, Blum A L etal. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
5. Wang C, Hunt R H. Medical management of gastroesophageal efflux disease. Gastroenterol Clin North Am 2008; 37: 879-99.
6. Fock K M, Talley N, Hunt R etal. Report of the Asia-Pacific consensus on the treatment of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19: 357-67.
7. Galmiche J P, Stephenson K. Treatment of gastroesophageal reflux disease in adults: an individual approach. Dig Dis 2004; 22: 148-60.
8. Miwa H, Sasaki M, Furuta T etal. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 2007; 26: 69-77.
9. May H A, Wilson C G, Hardy J G. Monitoring radiolabelled antacid preparation in the stomach. Int J Pharm 1984; 19: 169-76.
10. Washington N, Washington C, Wilson C G. Gastric distribution and residence time of anti-reflux formations. Int J Pharm 1987; 39: 163-71.
11. Washington N, Steele R J, Jackson S J, Washington C, Bush D. Pattern and acid reflux in patients with low-grade oesophagitis - the role of an anti-reflux agent. Aliment Pharmacol Ther 1998; 12: 53-8.
12. Armstrong D, Pare P, Pericak D, Pyzyk M. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 2849-57.
13. Carlsson R, Dent J, Bolling-Sternevald E etal. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023-9.
14. Midolo P D, Lambert J R, Russell E G, Lin S K. A practical single sample dry latex agglutination test for Helicobacter pylori antibody detection. J Clin Pathol 1995; 48: 969-71.
15. 13C urea breath test in Japanese patients. Helicobacter 2000; 5: 98-103.
16. Hoshihara Y. Endoscopic findings of GERD (in Japanese with English abstract). Nippon Rinsho (Jpn J Clin Med) 2004; 62: 1459-64.
17. Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol 2006; 41: 95-9.
18. Chevrel B. A comparative crossover study on the treatment of heartburn and epigastric pain: liquid Gaviscon and magnesium-alminium antacid gel. J Int Med Res 1980; 8: 300-2.
19. Washington N, Greaves J L, Iftikhar S Y. A comparison of gastroesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either liquid Gaviscon or Algicon Suspension. Aliment Pharmacol Ther 1992; 6: 579-88.
20. Miwa H, Minoo T, Hojo M etal. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20 (Suppl 1): 112-17.
21. Miyamoto M, Manabe N, Haruma K. Efficay of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for symptom of GERD (FSSG) on decision of treatment strategy. Intern Med 2010; 49: 1469-76.
22. Dean B B, Gano A D Jr, Knight K, Ofman J J, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64.
23. Long J D, Orlando R C. Nonerosive reflux disease: a pathophysiologic perspective. Curr Gastroenterol Rep 2008; 10: 200-7.
24. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
25. Chatfield S. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastroesophageal reflux disease. Curr Med Res Opin 1999; 15: 152-9.
26. Zentilin P, Dulbecco P, Savarino E etal. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. Aliment Pharmacol Ther 2001; 21: 29-34.
27. Mandel K G, Daggy B P, Brodie D A, Jacoby H I. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther 2000; 14: 669-90.
28. Korman M G, Nicholson L, Chan J G. In-vivo anti - reflux and raft properties of alginates. Aliment Pharmacol Ther 1990; 4: 615-22.
29. Marciani L, Little S L, Snee J etal. Echo-planar magnetic resonance imaging of Gaviscon alginate rafts in-vivo. J Pharm Pharmacol 2002; 54: 1351-6.
30. Hampson F C, Farndale A, Strugala V, Sykes J, Jolliffe I G, Dettmar P W. Alginate rafts and their characterisation. Int J Pharm 2005; 294: 137-47.
31. Taylor G, Warren S J, Kelleway I W, Patel B, Little S L. Gastric residence of Gaviscon Advance and Liquid Gaviscon in healthy volunteers. J Pharm Pharmacol 1997; 49: 73-9.
32. Odunsi S T, Vázquez-Roque M I, Camilleri M etal. Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity 2010; 18: 1579-84.
33. Stops F, Fell J T, Collett J H, Martini L G, Sharma H L, Smith A M. The use of citric acid to prolong the in vivo gastro-retention of a floating dosage form in the fasted state. Int J Pharm 2006; 308: 8-13.
34. Uemura N, Inokuchi H, Serizawa H etal. Efficay and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol 2008; 43: 670-8.
35. Talley N J, Armstrong D, Junghard O, Wiklund I. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006; 24: 371-6.
36. Labentz J, Nocon M, Lind T etal. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease. Am J Gastroenterol 2006; 101: 2457-62.
37. Fass R, Ofman J J. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901-9.
38. Nakamura T, Shirakawa K, Masuyama H, Sugaya H, Hiraishi H, Terano A. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther 2005; 21: 19-26.
39. Manabe N, Haruma K, Hata J etal. Clinical characteristics of Japanese dyspeptic patients: is the Rome III classification applicable? Scand J Gastroenterol 2010; 45: 567-72.
40. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-52.